Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-902 in advanced solid tumors
NCT07124117Phase 2Recruiting
- Sponsor
- OBI Pharma
- Start
- Aug 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of OBI-902 in solid tumor (advanced stage), sponsored by OBI Pharma. Started Aug 2025; status: recruiting.
02
Drugs
OBI-902
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07124117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124117.